RFA-AG-22-024 "Primary Care-Based Screening and Intervention Development for Prevention of Abuse in Older and Vulnerable Adults in the Context of Alzheimer's Disease and Related Dementias (R61/R33 Clinical Trial Required)
Funding Opportunity Purpose: The purpose of this funding opportunity announcement (FOA) is to support research that can lead to the development of evidence-based primary care screening tools and behavioral interventions to prevent abuse in at-risk older and vulnerable adults with mild cognitive impairment (MCI) and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) and their families. Specifically, this FOA invites R61/R33 applications proposing Stage I screening and behavioral intervention development and Stage III efficacy trials in primary care settings. Studies must directly address the priority research needs and gaps highlighted in the U.S. Preventive Services Task Force's 2018 final recommendation statement on Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening for the development and validation of the following:
Reliable and accurate screening instruments or assessments in primary care settings for older and vulnerable adults without recognized signs or symptoms of abuse (i.e., asymptomatic), and for their medical visit companions, at the time of diagnosis of MCI or AD/ADRD and subsequent primary care encounters; and/or
Brief and effective point-of-care psychoeducational and behavioral interventions for the prevention of all types of abuse.
Application Deadline: October 21, 2021
Award Budget
Application budgets for the R61 and R33 phases must reflect the actual needs of the proposed project.
For the R61 phase, the combined budget for direct costs may not exceed $750,000, with no more than $500,000 requested in any single year.
For the R33 phase, if awarded, the combined budget for direct costs may not exceed $3,000,000.
Award Project Period
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
The maximum project period for the R61 planning phase is two years.
The maximum project period for the R33 phase is three years.
Frequently Asked Questions
Responses to Frequently Asked Questions about RFA-AG-22-024 will be posted here: www.nia.nih.gov/research/dbsr/....
Scientific/Research Contact(s)
Melissa S. Gerald, Ph.D. National Institute on Aging (NIA) Telephone: 301-496-3136 Email: melissa.gerald@nih.gov